Success Stories: EB-1A Approval for Assistant Professor of Medicine in Pennsylvania in the Field of Rheumatology
We Received Another EB1-A (Alien of Extraordinary Ability) Approval on May 1st, 2014 for an Assistant Professor of Medicine in the Field of Rheumatology (Approval Notice)
General Field: Rheumatology
Position at the Time of Case Filing: Assistant Professor of Medicine
National Origin: India
Service Center: Texas Service Center (TSC)
Residence at the Time of Filing: Pennsylvania
Approval Notice Date: May 1, 2014
Processing Time: 20 days (2 days after requesting Premium Processing)
Case Summary:
In this case, the client that we had the opportunity to work with was an Assistant Professor of Medicine from India in the field of rheumatology. He had conducted his research on a highly specialized area focusing on identifying novel risk factors or biomarkers, exploring disease mechanisms, improving disease definitions, creating new diagnostic and prediction tools and improving quality of care for patients with myositis, rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, among other autoimmune diseases. This work had resulted in at least 36 peer-reviewed scientific articles published in leading journals and numerous presentations at national and international conferences and seminars. At the time that his case was filed, these publications been cited at least 498 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also conducted at least 100 paper reviews for distinctive, internationally-circulated journals related to his field. The importance of his research was confirmed in the following quote from an independent recommender, “The importance of this research is evident, as [he] provided evidence that rituximab was safe, well tolerated, and possessed a steroid sparing effect. As [he] explained in his research, steroids are a major cause of side-effects and complications in these patients and the ability for them to cut down on the requirement of steroid use is a remarkable advancement in myositis treatment. Most notably, this clinical study was the largest clinical trial ever completed related to myositis and provided important information related to this severe condition.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought remain in the United States to continue work in the area of extraordinary ability, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in just 20 days.